Scott T Garrett

Director Scott Garrett acquired 177,936 shares of HCWB via private placement at $1.40 (−78% from 52-week high), expanding holdings 697.7% to 203,441 shares

Scott T Garrett, a director of HCW Biologics, acquired 177,936 shares totaling $250,000.08 in a private placement transaction on 2026-05-22 at $1.40 per share. Because this is flagged as a private placement rather than a discretionary open-market purchase, it does not reflect conviction-driven buying. Garrett's prior two purchases at this ticker (2025-05-16 and 2025-05-08) both generated negative 90-day returns of −26.8% and −76.8%, with a zero win rate on timing at the 90-day mark. The company reported annual revenue growth of −97.9% and was unprofitable over its most recent full fiscal year, with market cap of $13.1M—a distressed financial profile that underscores the speculative character of this equity position. While the 30-day stock movement of +341.9% reflects recent volatility, the stock remains −78.0% from its 52-week high, signaling structural weakness rather than fundamental recovery.

Director GARRETT SCOTT T bought 13,423 shares of HCWB at $7.45, more than doubling holdings to 25,505 shares amid cluster buy by 5 other insiders in 14 days.

On 2025-05-16, director GARRETT SCOTT T purchased 13,423 shares of HCW Biologics Inc. (HCWB) at $7.45, increasing his holdings by 111.1% from 12,082 to 25,505 shares. This purchase occurs as part of a cluster pattern with 5 other insiders also buying within the past 14 days, suggesting coordinated or similar conviction at the current price. The transaction value of $100,001.35 represents a material commitment. Against current fundamentals—the company posted negative net income of $-2,196,875.00 and revenue contraction of -9.7% year-over-year on a $13.2M market cap—the accumulation raises questions about whether insiders see near-term recovery or if the purchases reflect other drivers. The stock is currently -81.5% from its 52-week high of $49.60 and trading at $9.18, having gained 30.2% over 30 days but declined 41.2% over 90 days, suggesting it is off recent lows but well below recent peaks.

Director Garrett Scott T bought 5,385 shares of HCWB at $26.00 (May 8); stock now -87.5% from 52-week high amid cluster buy by 5 other insiders.

Garrett Scott T, a Director at HCW Biologics Inc., purchased 5,385 shares at $26.00 on May 8, 2025, increasing his holdings by 80.4% to 12,082 shares. This transaction is notable in the context of significant market deterioration: the stock has declined 87.5% from its 52-week high of $49.60 and fallen 68.3% over the past 90 days, now trading at $6.18. The company reported a quarterly revenue of $426,423.00 but posted a net loss of $3,902,288.00, with annual revenue declining 9.7% year-over-year. The purchase coincides with a cluster pattern in which 5 other insiders also acquired shares within the past 14 days. While the cross-ticker track record shows a 100.00% well-timed rate on 1 prior sell, this reflects a limited dataset and does not establish same-ticker predictive accuracy. The gap between the transaction price ($26.00) and current market price ($6.18) warrants examination of whether conditions have materially changed since the filing date or whether the timing of this accumulation relative to the stock's recent decline holds investor relevance.